Albumin and bleed risk in rivaroxaban treated patients.
Wojakowski E, Cheruvil C, Hassan A, Holsen MR, Chen L, Rossi M, Wilcox N, Woodruff AE.
J Thromb Thrombolysis · journal article · DOI 10.1007/s11239-020-02092-w PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för rivaroxaban. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
39 hitsRivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia.
Farasatinasab M, Zarei B, Moghtadaei M, Nasiripour S, Ansarinejad N, Zarei M.
J Clin Pharmacol · journal article · DOI 10.1002/jcph.1635Rivaroxaban prevents VTE in orthopaedic surgery.
Lim GB.
Nat Rev Cardiol · comment; journal article · DOI 10.1038/s41569-020-0377-9Rivaroxaban reduces ischaemic events in patients with PAD.
Huynh K.
Nat Rev Cardiol · comment; journal article · DOI 10.1038/s41569-020-0385-9Monitoring of rivaroxaban levels in patients with class III obesity.
Pahlmeyer L, Huang J.
Am J Health Syst Pharm · journal article; case reports · DOI 10.1093/ajhp/zxaa096Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban.
Bauersachs R, Khorana AA, Lee AYY, Soff G.
Res Pract Thromb Haemost · review-article; review; journal article · DOI 10.1002/rth2.12327Rivaroxaban in patients undergoing surgical mitral valve repair.
Noohi F, Sadeghipour P, Kordrostami S, Shafe O, Maleki M, Kyavar M, Bakhshandeh H, Rezaei Y, Rokni M, Moosavi J, Amin A, Tashakori Beheshti A, Hosseini S.
J Thromb Thrombolysis · comparative study; clinical trial; journal article · DOI 10.1007/s11239-020-02046-2Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome.
Moll S.
Ann Intern Med · comment; journal article · DOI 10.7326/l20-0053Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Samama CM, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, Fisher W, Martínez-Martín J, Duverger D, Deygas B, Presles E, Cucherat M, Mismetti P, PRONOMOS Investigators.
N Engl J Med · comparative study; equivalence trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1913808Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban.
Stammler R, Legendre P, Cacoub P, Blanche P, Piette JC, Costedoat-Chalumeau N.
Lupus · journal article; case reports · DOI 10.1177/0961203320914363Fatigue after initiating rivaroxaban for venous thromboembolism.
Karlsvik TM, Borgenvik TL, Aadalen M, Utne K, Førsund E, Jørgensen CT, Holst R, Jelsness-Jørgensen LP, Ghanima W.
Res Pract Thromb Haemost · brief-report; journal article · DOI 10.1002/rth2.12312Role of rivaroxaban after TAVI.
Fernández-Ruiz I.
Nat Rev Cardiol · comment; journal article · DOI 10.1038/s41569-019-0317-8Effects of Rivaroxaban on Platelet Aggregation.
Hernandez-Juarez J, Espejo-Godinez HG, Mancilla-Padilla R, Hernandez-Lopez JR, Moreno JAA, Majluf-Cruz K, Moreno-Hernández M, Isordia-Salas I, Majluf-Cruz A.
J Cardiovasc Pharmacol · journal article · DOI 10.1097/fjc.0000000000000770Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Författaruppgift saknas
Med Lett Drugs Ther · journal articleAbsence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
Gong IY, Mansell SE, Kim RB.
Basic Clin Pharmacol Toxicol · research support, non-u.s. gov't; journal article · DOI 10.1111/bcpt.12005Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Turpie AG, Kreutz R, Llau J, Norrving B, Haas S.
Thromb Haemost · research support, non-u.s. gov't; review; consensus statement; journal article · DOI 10.1160/th12-03-0209Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM.
Thromb Res · review; journal article · DOI 10.1016/j.thromres.2012.09.004Drug interactions with rivaroxaban following total joint replacement surgery.
Kwong LM, Tong LM.
Ann Pharmacother · review; journal article · DOI 10.1345/aph.1r055The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2.
Gigi R, Salai M, Dolkart O, Chechik O, Katzburg S, Stern N, Somjen D.
Connect Tissue Res · research support, non-u.s. gov't; journal article · DOI 10.3109/03008207.2012.711867The in vitro anticoagulant effect of rivaroxaban in children.
Attard C, Monagle P, Kubitza D, Ignjatovic V.
Thromb Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.thromres.2012.07.009Emergency management of bleeding associated with old and new oral anticoagulants.
Peacock WF, Gearhart MM, Mills RM.
Clin Cardiol · review-article; review; journal article · DOI 10.1002/clc.22037[Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Helbing T, Bode C, Moser M.
Hamostaseologie · journal article; english abstract · DOI 10.5482/hamo-12-05-0005Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
Xu XS, Moore K, Burton P, Stuyckens K, Mueck W, Rossenu S, Plotnikov A, Gibson M, Vermeulen A.
Br J Clin Pharmacol · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1365-2125.2012.04181.xRivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
Ahrens I, Bode C.
Future Cardiol · review; journal article · DOI 10.2217/fca.12.26An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S, Ansell J.
Thromb Haemost · comparative study; review; journal article · DOI 10.1160/th12-02-0093Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M, J-ROCKET AF study investigators.
Circ J · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1253/circj.cj-12-0454Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S.
Vasc Health Risk Manag · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.2147/vhrm.s30064Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI.
Am J Cardiol · comparative study; journal article · DOI 10.1016/j.amjcard.2012.05.011Long-term benefits of preventing venous thromboembolic events.
Cohen AT.
Curr Med Res Opin · research support, non-u.s. gov't; review; evaluation study; journal article · DOI 10.1185/03007995.2012.688737Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients.
Clavé A, Fazilleau F, Dumser D, Lacroix J.
Orthop Traumatol Surg Res · comparative study; randomized controlled trial; journal article · DOI 10.1016/j.otsr.2011.12.005